Hyaluronan Hydrogels for the Local Delivery of Mesenchymal Stromal Cells to the Injured Vocal Fold

Hertegård, Stellan; Nagubothu, Srinivasa Rao; Malmström, Emma; Ström, Cecilia; Tamburini, Anna; Davies, Lindsay C.; Blanc, Katarina Le

doi:10.1089/scd.2019.0102

Cited by 13 publications

(22 citation statements)

References 242 publications

(264 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An excellent safety profile is in line with results from intravenous (IV) MSC administration [13,14]. We could not analyze engraftment or survival of the administered MSCs within this trial for ethical reasons, but in animal models, MSC mode of action has been demonstrated to be via a "hit and run" effect, with few cells persisting within the VF tissue over 1 month after injection [18][19][20][21][22][23]. VF scarring is a condition resulting in severe voice problems for which lasting effective treatment has been elusive.…”

Section: Discussionmentioning

confidence: 86%

“…We have furthermore confirmed the safety and effectiveness of delivering MSCs within HA hydrogel in vivo. These findings provided us with data supporting that HA could be safely used as a delivery vehicle where defects were of a critical size, providing a scaffold for the MSCs [23].…”

Section: Introductionmentioning

confidence: 72%

“…These clinical findings support our in vivo data outlining the ability of MSCs to exert longterm, indirect effects on the endogenous VF stroma, resulting in improved LP tissue architecture and healing. These findings were evidenced despite the fact that the administered cells were lost from the system within days of delivery [14,[19][20][21][22][23]. We administered MSC one time.…”

Section: Discussionmentioning

confidence: 98%

“…No patient was excluded because of leakage. Cell dosage was based on previous animal safety data and adjusted for difference in membranous VF volume between humans and rabbits [19][20][21][22][23]. The ethical permissions also included a second treatment arm where MSC was mixed with a HA gel scaffold.…”

Section: Vocal Fold Surgery and Msc Administrationmentioning

confidence: 99%

“…The ethical permissions also included a second treatment arm where MSC was mixed with a HA gel scaffold. We included 8 randomly chosen patients where the MSCs (cell dosage within the same ranges as above) were mixed with HA gel (Auxigel™; Termira AB, Stockholm, Sweden, [23,27]). The gel was prepared by mixing 0.9% (w/v) HA in phosphate-buffered saline (PBS; part A) with 0.1% (w/v) polyvinyl alcohol derivative in PBS (to induce crosslinking, part B) at a 3:1 ratio.…”

Section: Vocal Fold Surgery and Msc Administrationmentioning

confidence: 99%

See 4 more Smart Citations

Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Vocal fold (VF) scarring, caused by surgery or inflammation, often results in severe voice problems or aphonia. Effective lasting treatment is lacking. Previous in vitro and in vivo animal studies reported positive effects on VF scar resolution with mesenchymal stromal cell (MSC) implantation. The principal aim of this study was to examine safety aspects and secondly treatment efficacy vocal fold function in patients with VF scarring and severe voice problems. Methods: In this open-label phase I/II study, 16 patients were treated with surgical scar resection followed by injection of autologous MSCs (0.5-2 × 10 6 MSCs/patient). Patients were monitored 1 year for serious adverse events (SAE) or minor complications. Therapeutic efficacy on treated VFs was evaluated by measurement of VF vibrations using high-speed laryngoscopy (HSL) and phonation pressure threshold (PTP) for elasticity and VF function. Patients self-reported voice change using the Voice Handicap Index (VHI). Results: No SAE or minor side effects were reported. Video ratings of VF vibrations and digitized analysis of HSL and PTP were significantly improved for 62-75% of the patients (depending on parameter). Two patients showed deteriorated VF vibrations, but improved PTP. VHI was significantly improved in 8 patients, with the remaining experiencing no significant change. Conclusions: The results indicate that local injection of autologous MSC into scarred VFs with severe voice problems may offer a safe and feasible therapeutic option. VF vibration and elasticity were improved in approximately two thirds of treated patients. This clinical study is registered in clinicaltrials.gov (ID: NCT01981330). Retrospective registration of first patient (20130511). https//: register.clinicaltrials.gov/.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Introductionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 98%

Section: Vocal Fold Surgery and Msc Administrationmentioning

confidence: 99%

Section: Vocal Fold Surgery and Msc Administrationmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Novel application of bone marrow mesenchymal stem cells combined with hepatocyte growth factor on subacute vocal fold wound healing

Xu,

Meng,

Wang

et al. 2024

World j. otorhinolaryngol.-head neck surg.

View full text Add to dashboard Cite

ObjectivesVocal fold (VF) scar causes solemn vocal problems for patients with previous surgery or laryngeal injury. It is also a difficult management problem for clinicians since rare superior management methods are available at present. Previous research usually focuses on the acute period of VF wound repairing, with little attention on subacute period intervention. Bone marrow mesenchymal stem cells (BMMSCs) and hepatocyte growth factor (HGF) combinations that are applied to treat VF wounds are rarely reported. The current study investigated the effects of BMMSCs‐HGF application on the regeneration of the VF mucosa during the subacute period.MethodsA bilateral wound was generated by forceps in the VF of each New Zealand White rabbit. BMMSCs are based on the acellular dermal matrix as cell carriers. Various compounds (BMMSCs‐AMD complex with or without HGF) was injected into the wounded VF at 2‐ or 4‐weeks following injury. Animals were killed at 60 days postinjection. Imaging of excised larynges was performed with the transmission electron microscope (TEM), and Immunohistochemical (IHC) analysis was also conducted.ResultsCollectively, 18 rabbits accepted injury modeling, with two of them died before repairing intervention. IHC results indicated that type‐I collagen was significantly devalued in the cluster injected with BMMSCs‐HGF than simple application of BMMSCs. The results of TEM suggested that the BMMSCs‐HGF injection can significantly reduce the collagen score.ConclusionOur preliminary study suggests opening regenerative effects of intervention for VF subacute scaring, with BMMSCs‐HGF.

show abstract

Hydrogel encapsulation of mesenchymal stem cells-derived extracellular vesicles as a novel therapeutic approach in cancer therapy

Farahzadi,

Fathi,

Vandghanooni

et al. 2024

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Hyaluronan Hydrogels for the Local Delivery of Mesenchymal Stromal Cells to the Injured Vocal Fold

Abstract: You have the right to do your actions, but you should not worry about the results (Bhagavad Gita, Chapter 2-Stanza 47)

Cited by 13 publications

References 242 publications

Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study

Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study

Novel application of bone marrow mesenchymal stem cells combined with hepatocyte growth factor on subacute vocal fold wound healing

Hydrogel encapsulation of mesenchymal stem cells-derived extracellular vesicles as a novel therapeutic approach in cancer therapy

Contact Info

Product

Resources

About